News & Updates
Filter by Specialty:
CAR T-cell therapy may overcome poor prognosis tied to conventional tiNHL therapies
A real-world study presented at ASH 2024 shows that CD19 chimeric antigen receptor (CAR) T-cell therapy is highly effective and has an acceptable toxicity profile for individuals with transformed indolent non-Hodgkin lymphoma (tiNHL).
CAR T-cell therapy may overcome poor prognosis tied to conventional tiNHL therapies
17 Jan 2025
Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?
Disease activity, as measured by C-reactive protein (CRP), foecal calprotectin (FC), and endoscopic evaluation, does not significantly vary a year following the initiation of gender-affirming hormone (GAH) therapy in transgender and gender nonconforming patients with inflammatory bowel disease (IBD), as shown in a study presented at AIBD 2024.
Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?
15 Jan 2025
Add-on palbociclib may overcome resistance to anti-HER2 Tx, ET in HR+, HER2+ mBC
The addition of the CDK4/6 inhibitor palbociclib to anti-HER2 and endocrine therapy (ET) significantly improves progression-free survival (PFS) in patients with hormone receptor-positive, HER-positive (HR+, HER+) metastatic breast cancer (mBC) in the first-line setting, according to the results of the phase III AFT-38 PATINA trial.
